Form 4 for ORIC Oric Pharmaceuticals, Inc.
Accepted 2024-03-08 00:00:00 ET · period of report 2024-03-06 · accession 0001415889-24-007345 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-08 | 2024-03-06 | ORIC | Chacko Jacob | Pres AND CEO, Dir | S - Sale | $16.21 | -40.0K | 728.5K | -5% | -$648.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-06 | S | D | 40,000 | $16.21 | 728,544 | D | — | — | (F2) Represents the weighted average share price of an aggregate total of 40,000 shares sold in the price range of $16.00 to $16.43 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |